Q-omics provides the consensus-scored PRANCR profile across patient tissues and cancer cell-line models. PRANCR expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRANCR is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, PRANCR RNA expression shows 17,802 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where PRANCR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRANCR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRANCR survival associations across molecular data types. PRANCR RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRANCR RNA expression–survival associations across cancer types. High PRANCR expression shows unfavorable associations in ACC, KIRC and LIHC, but favorable associations in PAAD, BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRANCR RNA expression.
This table summarizes PRANCR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRANCR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRANCR shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, LIHC, HNSC and KIRC. The BLCA box plot shows higher PRANCR RNA expression in tumor versus normal tissue (log2 FC = +0.949, t-test p < 0.001).
This table shows molecular features associated with PRANCR in patient tissues and cancer cell lines. In patient samples, PRANCR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
